The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.

The invention provides methods, kits, compositions, and devices useful for detection of antibodies that bind to Ehrlichia antigens and/or for differentiation of certain Ehrlichia species from others. In particular, the invention provides methods and kits useful for identifying species of Ehrlichia using populations of isolated peptides.

The invention provides populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens. The peptide populations comprise peptides derived from immunogenic fragments of the Anaplasma Outer Membrane Protein proteins. The invention also provides devices, methods, and kits comprising the populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens and the diagnosis of anaplasmosis. Methods of identifying the particular Anaplasma species infecting a subject using the peptide populations of the invention are also disclosed.

The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.

The present invention concerns gp36 immunoreactive compositions for E. canis and gp 47 immunoreactive compositions for E. chaffeensis. In particular, epitopes for E. canis gp36 and E. chaffeensis gp 47 are disclosed. In certain embodiments, the immunoreactive compositions comprise tandem repeats having carbohydrate moieties.

Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.

The invention provides populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens. The peptide populations comprise peptides derived from immunogenic fragments of the Anaplasma Outer Membrane Protein proteins. The invention also provides devices, methods, and kits comprising the populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens and the diagnosis of anaplasmosis. Methods of identifying the particular Anaplasma species infecting a subject using the peptide populations of the invention are also disclosed.

The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions and mixtures comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic and/or granulocytic ehrlichiosis.

The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.

The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.